Publish in this journal
Journal Information
Vol. 67. Issue 11.
Pages 967-968 (November 2014)
Vol. 67. Issue 11.
Pages 967-968 (November 2014)
Letter to the Editor
Full text access
Red Cell Distribution Width and Coronary Artery Disease
Amplitud de distribución eritrocitaria y enfermedad coronaria
Yavuzer Koza
Department of Cardiology, Ataturk University Faculty of Medicine, Erzurum, Turkey
Related content
Marianela Sánchez-Martínez, Angel López-Cuenca, Francisco Marín, Pedro J. Flores-Blanco, Andrea García Narbon, Ignacio de las Heras-Gómez, María J. Sánchez-Galian, Mariano Valdés-Chávarri, James L. Januzzi, Sergio Manzano-Fernández
Rev Esp Cardiol. 2014;67:968-910.1016/j.rec.2014.07.003
Marianela Sánchez-Martínez, Ángel López-Cuenca, Francisco Marín, Sergio Manzano-Fernández
This item has received
Article information
Full Text
Download PDF
Full Text
To the Editor,

Red cell distribution width (RDW) has traditionally been considered useful in the differential diagnosis of anemia. RDW, which is routinely reported in complete blood counts as a statistical concept, is a measure of the variation in red blood cell volume.1

In recent years, interest has significantly increased in RDW as a risk marker in cardiovascular research. Several studies have shown that high RDW levels are associated with higher mortality among patients with heart failure,2 coronary artery disease,3 or myocardial infarction,4 and in those undergoing percutaneous coronary intervention.5

In a recent study published in Revista Española de Cardiología, Sánchez-Martínez et al6 showed that in non–ST-segment elevation acute coronary syndrome patients, elevated RDW values were predictive of increased major bleeding risk and provided additional information to the CRUSADE scale. The authors studied 293 consecutive patients with an established final diagnosis of high-risk unstable angina or non-ST segment elevation myocardial infarction.

The authors measured RDW values only at admission and did not collect data on bleeding events or stent thrombosis during hospitalization. Increased RDW levels are also associated with aging, sex, genetic factors, thyroid diseases, renal or hepatic dysfunction, inflammatory disease, nutritional deficiency, and medications.7

Sánchez-Martínez et al6 grouped anemic and nonanemic patients together in the analysis. However, in patients with acute coronary syndrome, functional iron deficiency anemia can be seen as a result of increased synthesis of hepcidin in the liver.8 Hepcidin, a peptide hormone, is also found in the heart and its expression is regulated by hypoxia and inflammation. An increased level of hepcidin inhibits the absorption of iron from the intestinal epithelium and blocks iron release from macrophages.8,9 As iron has detrimental effects in arteriosclerosis and ischemia/reperfusion,10 an elevated RDW value in patients with coronary artery disease possibly indicates functional iron deficiency anemia rather than worse clinical outcomes. It can be speculated that elevated RDW values are a reflection of reduced iron-toxicity in the infarcted myocardium.

In addition, a recent study by Meroño et al11 showed that nosocomial anemia without apparent bleeding in patients with acute coronary syndrome was a frequent complication (25%) and a predictor of mortality and cardiovascular complications during the first year of follow-up. Nosocomial anemia was associated with a marked inflammatory state, indicated by increased C-reactive protein levels.

Finally, the authors suggest that future research should assess the potential role of including RDW values in bleeding risk scales to improve the stratification of non-ST-segment elevation acute coronary syndrome patients, especially after hospital discharge. Should physicians be alerted to a higher risk of major bleeding by the presence of a higher RDW without a universally accepted cut-off value and a single measurement of RDW alone without taking into consideration other inflammatory indicators? If so, while the imprecision values are not defined, is it useful to follow RDW as a surrogate marker of subsequent adverse outcomes, much as a diabetologist follows glycated hemoglobin? More importantly, how can we manipulate the RDW to improve outcomes? Thus, when a mechanism explaining the association of RDW with adverse outcome is developed and definitive interventions to reduce RDW are identified, it will become a member of the standard evaluation test panel for our patients. Currently, the only clear thing about RDW is its ability to predict adverse outcomes.

R.T. Means Jr..
Free and easy? Red cell distribution width (RDW) and prognosis in cardiac disease.
J Card Fail., 17 (2011), pp. 299-300
G.M. Felker, L.A. Allen, S.J. Pocock, L.K. Shaw, J.J. McMurray, M.A. Pfeffer, et al.
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
J Am Coll Cardiol., 50 (2007), pp. 40-47
M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer.
Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease.
Circulation., 117 (2008), pp. 163-168
S. Dabbah, H. Hammerman, W. Markiewicz, D. Aronson.
Relation between red cell distribution width and clinical outcomes after acute myocardial infarction.
Am J Cardiol., 105 (2010), pp. 312-317
O. Fatemi, J. Paranilam, A. Rainow, K. Kennedy, J. Choi, D. Cutlip, et al.
Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention.
J Thromb Thrombolysis., 35 (2013), pp. 57-64
M. Sánchez-Martínez, A. López-Cuenca, F. Marín, P.J. Flores-Blanco, A. García Narbon, I. De las Heras-Gómez, et al.
Ancho de distribución eritrocitaria y predicción adicional del riesgo de hemorragia mayor en el síndrome coronario agudo sin elevación del ST.
Rev Esp Cardiol., (2014),
G. Lippi, G.L. Salvagno, G.C. Guidi.
Red blood cell distribution width is significantly associated with aging and gender.
Clin Chem Lab Med., (2014),
T. Ganz.
Hepcidin and iron regulation, 10 years later.
Blood., 117 (2011), pp. 4425-4433
U. Merle, E. Fein, S.G. Gehrke, W. Stremmel, H. Kulaksiz.
The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation.
Endocrinology., 148 (2007), pp. 2663-2668
B. De Valk, J.J. Marx.
Iron, atherosclerosis, and ischemic heart disease.
Arch Intern Med., 159 (1999), pp. 1542-1548
O. Meroño, M. Cladellas, L. Recasens, C. Garcia-Garcia, N. Ribas, V. Bazan, et al.
Anemia adquirida en el síndrome coronario agudo. Predictores. pronóstico intrahospitalario y mortalidad a un año.
Rev Esp Cardiol., 65 (2012), pp. 742-748
Copyright © 2014. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?